BRIEF—J&J and Otsuka agree Japanese commercialization strategy for Tremfya

Tokyo’s Taiho Pharmaceutical, an Otsuka subsidiary focused on oncology, has signed a deal with J&J’s pharmaceuticals arm Janssen to co-promote Tremfya (guselkumab) in Japan.

Under the terms of the agreement, the companies will market the IL-23 monoclonal antibody for psoriasis and palmoplantar pustulosis in Japan, pending regulatory approval in these indications.

Taiho gains the right to distribute the therapy. Janssen filed for approval in Japan in April 2017.